Miltefosine (Impavido): the first oral treatment against leishmaniasis期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Miltefosine (Impavido): the first oral treatment against leishmaniasis

Authors:	H.?Sindermann,S.?L.?Croft,K.?R.?Engel,W.?Bommer,H.?J.?Eibl,C.?Unger,J.?Engel author-information" > author-information__contact u-icon-before" > mailto:Juergen.engel@zentaris.de" title=" Juergen.engel@zentaris.de" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author

Affiliation:	(1) Zentaris AG, Weismüllerstrasse 45, 60314 Frankfurt am Main, Germany;(2) London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK;(3) Georg-August-University of Göttingen, Institute of Hygiene, Windausweg 2, 37073 Göttingen, Germany;(4) Max-Planck-Institut für Biophysikalische Chemie, Am Fassberg, 37077 Göttingen, Germany;(5) Klinik für Tumorbiologie, Breisacher Strasse 117, 79106 Freiburg, Germany

Abstract:	Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

Keywords:	Visceral leishmaniasis Miltefosine Oral activity Antimonial resistance
本文献已被 PubMed SpringerLink 等数据库收录！